



## Poly ADP-Ribose Polymerase (PARP) Inhibitors for Ovarian Cancer: Effectiveness and Value

Thursday, September 14, 2017; 10:00 AM – 4:00 PM

### Agenda

Century Room BC, Millenium Student Center  
 University of Missouri-St. Louis  
 1 University Blvd. St. Louis, MO 63121

Time	Activity
9:30 am – 10:00 am	Registration
10:00 am – 10:15 am	<b>Meeting Convened and Opening Remarks:</b> <ul style="list-style-type: none"> <li>Eric Armbrecht, PhD, Chair, Midwest CEPAC</li> <li>Steven Pearson, MD, MSc, President, ICER</li> </ul>
10:15 am – 11:15 am	<b>Presentation of the Evidence:</b> <ul style="list-style-type: none"> <li>Lipika Samal, MD, Harvard Medical School</li> <li>R. Brett McQueen, PhD, University of Colorado</li> </ul>
11:15 am – 11:45 am	Manufacturer Comments and Discussion
11:45 am – 12:15 pm	<b>Public Comments and Discussion:</b> <i>Members of the public pre-registered to deliver oral remarks</i>
12:15 pm – 1:00 pm	Break for Lunch
1:00 pm – 2:30 pm	<b>Midwest CEPAC Q&amp;A with Clinical Experts</b> <b>Midwest CEPAC Deliberation and Votes:</b> <i>ICER staff and clinical experts will be available for questions from the Council during deliberation</i>
2:30 pm – 3:30 pm	Policy Roundtable
3:30 pm – 4:00 pm	Final Comments and Adjournment

## Meeting Participants

### Midwest CEPAC Panel

Name	Organization	Disclosure
<b>Eric Armbrrecht, PhD</b>	St Louis University Center for Health Outcomes Research	*
<b>Ryan Barker, MSW, MPPA</b>	Missouri Foundation for Health	*
<b>Donald Casey, MD, MPH, MBA</b>	Medecision; IPO4Health; Jefferson College of Population Health; Rush Medical College	*
<b>Rena Conti, PhD</b>	University of Chicago	*
<b>Jill Johnson, Pharm. D.</b>	University of Arkansas for Medical Sciences	*
<b>Bill Moore, PhD</b>	REACH Healthcare Foundation	*
<b>Harold Pollack, PhD</b>	University of Chicago	*
<b>Scott Micek, Pharm. D.</b>	St. Louis College of Pharmacy	*
<b>Rachel Sachs, JD, MPH</b>	Washington University in St. Louis	*
<b>Shumei Yun, MD, PhD</b>	MO Department of Health and Senior Services	*

\*No conflicts of interest to disclose, defined as more than \$10,000 in health care company stock or more than \$5,000 in honoraria or consultancies during the previous year from relevant health care manufacturers or insurers.

### Policy Roundtable Participants

- **Harold Carter**, Express Scripts
- **Susan Leighton**, Patient
- **Betsy Neisner**, Patient
- **Matthew Powell, MD**, Washington University at St. Louis
- **Andrea Wahner Hendrickson, MD**, Mayo Clinic

### Institute for Clinical and Economic Review (ICER) Staff and Consultants

- **Steve Pearson, MD, MSc**, President, ICER
- **Daniel Ollendorf, PhD**, Chief Scientific Officer, ICER
- **Lipika Samal, MD**
- **Jonathan Campbell, PhD**, University of Colorado
- **R. Brett McQueen, PhD**, University of Colorado
- **Patricia Synnott, MALD, MS**, Senior Research Associate ICER
- **Geri Cramer, BSN, MBA**, Research Associate
- **Sonya Khan, MPH**, Program Director, ICER
- **Molly Morgan**, Program and Event Coordinator, ICER